裕同科技(002831.SZ)籌劃推出第二期員工持股計劃
格隆匯11月30日丨裕同科技(002831.SZ)公佈,公司計劃籌備、推出第二期員工持股計劃,本員工持股計劃設立後,將委託信託公司設立集合資金信託計劃。集合信託計劃委託金額上限預計為6.6億元,份額上限預計為6.6億份,按照1:1設立優先信託份額和一般信託份額,優先信託份額的規模上限預計為3.3億份,一般信託份額的規模上限預計為3.3億份。集合信託計劃優先信託份額和一般信託份額的資產將合併運作。員工持股計劃籌集資金全額認購集合信託計劃的一般信託份額。
員工持股計劃的股票來源為公司回購專用證券賬户回購的股票(股票總數668.97萬股)以及通過二級市場以大宗交易或集中競價等法律法規允許的方式購買的公司股票。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.